Mitochondrial Disorders 1
The Mitochondrial Disorders 1 session will be discussing Molecular and enzymatic diagnosis; biomarkers; therapies in mitochondrial disorders.
Commercial Supporter
This educational activity is supported by an educational grant from Ultragenyx.
Learning Objectives
- Appreciate current diagnostic approach to suspected mitochondrial disease.
- Recognize highly heterogeneous dual genome etiology of primary mitochondrial disease.
- Consider the increasing number of novel treatment approaches for primary mitochondrial disease.
Guest Faculty
Marni Falk, MD
Executive Director, Mitochondrial Medicine Frontier Program
Distinguished Chair in the Department of Pediatrics
Professor, Division of Human Genetics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine
Children's Hospital of Philadelphia
Disclosures
Marni Falk, MD, speaker for this session, is a consultant for Standigm Therapeutics, Inc., Primera Therapeutics, Precision Biosciences, and Sanofi, a sponsored research collaborator for Saol Therapeutics and Sanofi, and a co-founder and chief scientific officer for Rarefy Therapeutics.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Medical
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Others
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance